The California Institute for Regenerative Medicine approved a $100 million RAPID program to fund platform‑based in‑vivo genetic therapies for rare diseases, shifting from single‑asset funding toward scalable delivery models. In parallel, PrimeGen US filed to go public via a SPAC merger to raise capital for its mesenchymal stem‑cell and exosome programs targeting liver disease. Together these steps reflect growing investment and institutional support for platform approaches to accelerate clinical translation of genetic and regenerative medicines.